The Company's 2014 financial guidance has been revised and is summarized below.2014 Financial Guidance SummaryPreviousCurrentTotal revenues
$146 million - $150 million
4% - 7% growth
$144 million - $146 million
2% - 4% growthProduct revenues
Mid to high single-digit % growth
SameTissue processing revenues
Low single-digit % growth
$11.0 million - $12.0 million
SameEarnings per share
$0.17 - $0.20, including litigation
SameIncome tax rate
Approximately 30%The Company's earnings per share guidance includes estimated expenses related to the previously disclosed declaratory judgment action filed by the Company against C.R. Bard, Inc. and certain of its subsidiaries. Earnings per share guidance does not include expenses related to future business development activities and the effect of share repurchases, which cannot currently be estimated.
The Company's financial guidance for the full year of fiscal 2014 is subject to the risks described below in the last paragraph of this press release, prior to the financial tables.
Webcast and Conference Call InformationThe Company will hold a teleconference call and live webcast today at 10:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Anderson.
To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available July 24 through July 31 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13586553.
|SOURCE CryoLife, Inc.|
Copyright©2014 PR Newswire.
All rights reserved